SCHEDULE: Corvus Capital Proposes $2/Share Takeover of CDT Equity

Sentiment:

Schedule 13D Amendment 6 November 2026 9:15 AM

📋All filings for Conduit Pharmaceuticals INC

Corvus Capital, a major shareholder, has proposed acquiring all outstanding shares of CDT Equity Inc. not already owned by the reporting persons at $2.00 per share, a significant premium to the current market price.

Capital raiseCorvus Capital has requested that CDT Equity Inc. suspend its at-the-market offering program.The filing notes that the company's cash position and going-concern qualification leave it dependent on continuous equity issuance to raise capital.The proposed acquisition price of $2.00 per share is significantly higher than the current market price, implying a substantial capital requirement for Corvus Capital to execute the takeover.

Worse than expectedThe unsolicited takeover bid at a significant premium suggests that the current market valuation and management's strategy are not meeting the expectations of a major shareholder.The company's reliance on at-the-market offerings at a fraction of net asset value, combined with reverse stock splits, indicates a struggle to maintain value and potentially dilutes existing shareholders.The significant discount between the company's market capitalization and the reported value of its assets points to underlying issues with investor confidence or the company's ability to monetize its holdings.

Summary

Corvus Capital Ltd., along with Andrew Regan and Manoira Corporation, collectively hold 22.1% of CDT Equity Inc. (CDT) shares as of October 26, 2026.
On November 5, 2026, Corvus Capital sent a letter to CDT's board expressing concerns about the company's market valuation, capital raising, and asset value.
Corvus Capital proposed acquiring all outstanding CDT shares not already owned by the reporting persons at $2.00 per share.
This proposed price represents a 96.3% premium over CDT's closing price of $1.018 on November 4, 2026.
Corvus Capital requested that CDT suspend its at-the-market offering program, form a committee of independent directors to evaluate the proposal, and appoint at least one additional independent director.
The proposed transaction is subject to due diligence, definitive documentation, board recommendation, shareholder and regulatory approvals.
CDT Equity Inc. was formerly known as Conduit Pharmaceuticals Inc.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the unsolicited takeover bid at a significant premium, indicating potential dissatisfaction with the current management and valuation.

Positives

The proposed $2.00 per share offer represents a significant premium (96.3%) over the current market price, potentially benefiting existing shareholders.
The proposal aims to address concerns regarding CDT's market valuation and asset value, potentially unlocking shareholder value.
Corvus Capital is requesting the formation of an independent committee to evaluate the offer and alternatives, promoting a structured review process.

Negatives

The unsolicited takeover bid suggests dissatisfaction with the current management and strategic direction of CDT Equity Inc.
The company's reliance on continuous equity issuance and at-the-market offerings at a fraction of net asset value is diluting existing shareholders.
The company's shares are trading at a significant discount to the value of its underlying assets, particularly its holding in Sarborg.
The company's cash position and going-concern qualification in its accounts indicate financial vulnerability.

Risks

There is no assurance that the proposed transaction will be made, agreed upon, or consummated.
The company's current financing activities are eroding the value of Sarborg for existing shareholders.
The company's shares are trading at a fraction of the value of its assets, creating a significant discount.
The company's financial health may be dependent on continuous equity issuance, leading to further dilution.

Future Outlook

The reporting persons intend to continue reviewing their investment in CDT Equity Inc. and may engage in discussions with the board, management, or other stockholders regarding the potential transaction, strategic alternatives, capitalization, financing, corporate governance, or other matters. Depending on various factors, they may consider additional courses of action.

Management Comments

Corvus Capital delivered a letter to the Issuer's board of directors expressing concerns with respect to the Issuer's current market valuation, capital raising activities and the value of its assets.
Corvus expressed its intent to propose an acquisition of all of the outstanding shares of Common Stock not already beneficially owned by the Reporting Persons at a purchase price of $2.00 per share.
Corvus believes that the Board can and should act to reduce the gap between the company's share price and the value of its assets for all shareholders.
Corvus believes that shareholders should not be left holding an asset the market does not recognise while the company's own financing erodes their share of it.
In the absence of a proposal from the Board to address these concerns, cement a license deal, develop its Pharmaceutical assets or further address a significant enhancement to shareholder value, Corvus intends to make a proposal to acquire the entire issued share capital of CDT Equity Inc. at a price of $2.00 per share.

Industry Context

StockSavvy.ai notes that unsolicited takeover bids often arise when activist investors perceive a significant undervaluation of a company's assets relative to its market capitalization, especially in sectors with tangible assets like pharmaceuticals or biotech where asset value can be more readily assessed. The company's use of reverse stock splits to maintain exchange listing compliance, coupled with at-the-market offerings, is a common, albeit often dilutive, strategy for companies facing cash flow challenges.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Committee Formation Request	Corvus Capital requested the formation of a committee of independent directors to evaluate the potential transaction and other alternatives available to the Issuer.	Not specified, pending board consideration	Could lead to a more objective review of the takeover proposal and strategic options.
Independent Director Appointment Request	Corvus Capital requested that the Issuer's board of directors strengthen its independent oversight by appointing at least one additional independent director.	Not specified, pending board consideration	Aims to enhance corporate governance and potentially provide a more balanced decision-making process.

Stakeholder Impact

Shareholders: Potential for a significant return on investment if the $2.00 per share offer is accepted, but also risk of continued dilution if the offer is rejected and the company continues its current financing strategy.
Creditors: The company's financial stability and ability to meet obligations could be impacted by the outcome of the takeover bid and any subsequent strategic changes.
Management: The current management team's position is challenged by the unsolicited bid and the criticisms leveled by Corvus Capital.

Next Steps

Corvus Capital intends to engage with the Issuer's board of directors regarding the potential acquisition and alternatives.
Corvus Capital requested that the Issuer's board of directors suspend the at-the-market offering program.
Corvus Capital requested that the Issuer's board of directors form a committee of independent directors to evaluate the potential transaction and alternatives.
Corvus Capital requested that the Issuer's board of directors strengthen independent oversight by appointing at least one additional independent director.
The Issuer's board of directors is expected to respond in writing within 5 days of November 5, 2026.
The company's board will consider the matters raised in Corvus Capital's letter.

Key Dates

Date	Description
2023-09-29	Original Schedule 13D filing date.
2024-09-19	Filing date of Amendment No. 1 to the Original Schedule 13D.
2025-07-31	Filing date of Amendment No. 2 to the Original Schedule 13D.
2025-09-22	Filing date of Amendment No. 3 to the Original Schedule 13D.
2025-12-22	Filing date of Amendment No. 4 to the Original Schedule 13D.
2026-05-14	Filing date of Amendment No. 5 to the Original Schedule 13D.
2026-07-20	Date of the July Reverse Split.
2026-09-02	Filing date of Amendment No. 6 to the Original Schedule 13D.
2026-09-28	Date of the September Reverse Split.
2026-10-23	Date as of which shares of Common Stock outstanding were provided by the Issuer.
2026-10-26	Date as of which shares of Common Stock are reported by reporting persons.
2026-10-27	Filing date of Amendment No. 7 to the Original Schedule 13D.
2026-11-04	Closing price of CDT Equity Inc. shares.
2026-11-05	Date of the Corvus Letter to the Issuer's Board of Directors.
2026-11-06	Date of signatures on the Schedule 13D filing.

Recommendation

hold

The unsolicited bid at a significant premium presents a clear potential upside for shareholders. However, the outcome is uncertain, and the company's underlying financial issues and management's response need to be considered. A 'hold' recommendation allows investors to await further developments, such as the board's response and the potential for negotiation or alternative offers, before making a definitive decision.

Keywords

takeover bid, asset valuation, shareholder value, capital raising, corporate governance, reverse stock split, at-the-market offering, independent directors

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.